Conference Call with Syngene International Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Syngene International announced Q1FY26 results Revenue from Operations: Rs 875 crore compared to Rs 790 crore during Q1FY25, change 11%. Revenue: Rs 892 crore compared to Rs 808 crore during Q1FY25, change 10%. EBITDA: Rs 224 crore compared to Rs 188 crore during Q1FY25, change 19%. EBITDA Margin: 23% for Q1FY26. PAT: Rs 87 crore compared to Rs 54 crore during Q1FY25, change 59%. PAT Margin: 7% for Q1FY26. Peter Bains, Managing Director and CEO, Syngene International, said: “We are pleased with the growth performance in the first quarter, which is aligned with our expectations. Continued conversion of pilot programs into longer-term contracts within our Research Services business was the main driver underpinning this momentum. In our Biologics manufacturing division, we have seen good progress with the start of operations at the Unit III facility in Bengaluru and in advancing preparations to commence operations at our Bayview facility in the U.S later this year. We continued to strengthen and expand our scientific platform capabilities, bringing online a state-of-the-art, dedicated peptide laboratory. While we remain mindful of ongoing macroeconomic factors, we maintain a confident outlook.” Deepak Jain, Chief Financial Officer, Syngene International, said: “We are pleased with the growth in revenue from operations of 11% year-on-year. Operating EBITDA margins came at around 24%, driven by both revenue growth and a focus on cost optimization. The current quarter’s PAT includes a tax benefit arising from transfer of gratuity funds to Employee Gratuity Trust. We continue to maintain a robust balance sheet enabling us to invest in technology and capabilities to strengthen our customer offerings. While keeping a close watch on market trends, we remain on course to deliver in line with our stated guidance for the year.” Result PDF